Skip to main content

Advertisement

SpringerLink
Log in

Genetic variation in the natriuretic peptide system and heart failure

  • Published:
Heart Failure Reviews Aims and scope Submit manuscript

Abstract

Heart failure (HF) is a modern epidemic and is one of the few cardiovascular diseases which is increasing in prevalence. The growing importance of the Natriuretic Peptide (NP) system in HF is well recognized. Laboratory tests for B-type Natriuretic Peptide (BNP) have proven value as diagnostic and prognostic tools in HF and are now part of routine clinical care. Furthermore, recombinant atrial natriuretic peptide (ANP) (carperitide) and BNP (nesiritide) and are approved HF therapies in Japan and the US, respectively and additional natriuretic peptides (e.g., CNP, urodilatin, and designer NPs) are under investigation for use in HF. Common genetic sequence variants are increasingly being recognized as determinants of disease risk or drug response and may help explain a portion of the inter-individual variation in the human NP system. This review describes current knowledge of NP system genetic variation as it pertains to HF as well as ongoing studies and where the field is expected to progress in the near future. To briefly summarize, NP system genetic variants have been associated with alterations in gene expression, NP levels, and cardiovascular disease. The next step forward will include specific investigations into how this genetic variation can advance ‘Personalized Medicine’, such as whether they impact the utility of diagnostic BNP testing or effectiveness of therapeutic NP infusion. This is already in progress, with pharmacogenetic studies of nesiritide currently underway. We expect that within 5 years there should be a reasonable idea of whether NP system genetic variation will have important clinical implications.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

References

  1. McCullough PA, Philbin EF, Spertus JA, Kaatz S, Sandberg KR, Weaver WD (2002) Confirmation of a heart failure epidemic: findings from the Resource Utilization Among Congestive Heart Failure (REACH) study. J Am Coll Cardiol 39(1):60–69

    Article  PubMed  Google Scholar 

  2. American Heart Association (2004) Heart disease and stroke statistics—2005 Update. http://www.americanheart.org/presenter.jhtml?identifier=1928. Accessed 2004

  3. Jessup M, Brozena S (2003) Heart failure. N Engl J Med 348(20):2007–2018

    Article  PubMed  Google Scholar 

  4. Popovic JR, Hall MJ (1999) National hospital discharge survey. Hyattsville, Maryland: Center for Disease Control, National Center for Health Statistics; 2001 April 24. Report No.: 319

  5. Chen HH, Burnett JC Jr (1999) The natriuretic peptides in heart failure: diagnostic and therapeutic potentials. Proc Assoc Am Physicians 111(5):406–416

    CAS  PubMed  Google Scholar 

  6. Maisel AS, Krishnaswamy P, Nowak RM et al (2002) Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med 347(3):161–167

    Article  CAS  PubMed  Google Scholar 

  7. Scios JJ Nesiritide Prescribing Information P0101208

  8. Suwa M, Seino Y, Nomachi Y, Matsuki S, Funahashi K (2005) Multicenter prospective investigation on efficacy and safety of carperitide for acute heart failure in the ‘real world’ of therapy. Circ J 69(3):283–290

    Article  PubMed  Google Scholar 

  9. Nabel EG (2003) Cardiovascular disease. N Engl J Med 349(1):60–72

    Article  CAS  PubMed  Google Scholar 

  10. Evans WE, McLeod HL (2003) Pharmacogenomics—drug disposition, drug targets, and side effects. N Engl J Med 348(6):538–549

    Article  CAS  PubMed  Google Scholar 

  11. Lanfear DE, McLeod HL (2007) Pharmacogenetics: using DNA to optimize drug therapy. Am Fam Physician 76(8):1179–1182

    PubMed  Google Scholar 

  12. Nakayama T (2005) The genetic contribution of the natriuretic peptide system to cardiovascular diseases. Endocr J 52(1):11–21

    Article  CAS  PubMed  Google Scholar 

  13. LaPointe MC, Yang XP, Carretero OA, He Q (2002) Left ventricular targeting of reporter gene expression in vivo by human BNP promoter in an adenoviral vector. Am J Physiol Heart Circ Physiol 283(4):H1439–H1445

    CAS  PubMed  Google Scholar 

  14. Stoupakis G, Klapholz M (2003) Natriuretic peptides: biochemistry, physiology, and therapeutic role in heart failure. Heart Dis 5(3):215–223

    Article  CAS  PubMed  Google Scholar 

  15. Koller KJ, Goeddel DV (1992) Molecular biology of the natriuretic peptides and their receptors. Circulation 86(4):1081–1088

    CAS  PubMed  Google Scholar 

  16. Almirez R, Protter AA (1999) Clearance of human brain natriuretic peptide in rabbits; effect of the kidney, the natriuretic peptide clearance receptor, and peptidase activity. J Pharmacol Exp Ther 289(2):976–980

    CAS  PubMed  Google Scholar 

  17. Rose RA, Giles WR (2008) Natriuretic peptide C receptor (NPR-C) signaling in the heart and vasculature. J Physiol 586(2):353–366

    Google Scholar 

  18. Kuhn M (2003) Structure, regulation, and function of mammalian membrane guanylyl cyclase receptors, with a focus on guanylyl cyclase-A. Circ Res 93(8):700–709

    Article  CAS  PubMed  Google Scholar 

  19. Sabrane K, Kruse MN, Fabritz L et al (2005) Vascular endothelium is critically involved in the hypotensive and hypovolemic actions of atrial natriuretic peptide. J Clin Invest 115(6):1666–1674

    Article  CAS  PubMed  Google Scholar 

  20. Holtwick R, Gotthardt M, Skryabin B et al (2002) Smooth muscle-selective deletion of guanylyl cyclase-A prevents the acute but not chronic effects of ANP on blood pressure. Proc Natl Acad Sci USA 99(10):7142–7147

    Article  CAS  PubMed  Google Scholar 

  21. Ellmers LJ, Knowles JW, Kim HS, Smithies O, Maeda N, Cameron VA (2002) Ventricular expression of natriuretic peptides in Npr1(-/-) mice with cardiac hypertrophy and fibrosis. Am J Physiol Heart Circ Physiol 283(2):H707–H714

    CAS  PubMed  Google Scholar 

  22. Ellmers LJ, Scott NJ, Piuhola J et al (2007) Npr1-regulated gene pathways contributing to cardiac hypertrophy and fibrosis. J Mol Endocrinol 38(1–2):245–257

    Article  CAS  PubMed  Google Scholar 

  23. Vellaichamy E, Kaur K, Pandey KN (2007) Enhanced activation of pro-inflammatory cytokines in mice lacking natriuretic peptide receptor-A. Peptides 28(4):893–899

    Article  CAS  PubMed  Google Scholar 

  24. Kapoun AM, Liang F, O’Young G et al (2004) B-type natriuretic peptide exerts broad functional opposition to transforming growth factor-beta in primary human cardiac fibroblasts: fibrosis, myofibroblast conversion, proliferation, and inflammation. Circ Res 94(4):453–461

    Article  CAS  PubMed  Google Scholar 

  25. John SW, Veress AT, Honrath U et al (1996) Blood pressure and fluid-electrolyte balance in mice with reduced or absent ANP. Am J Physiol 271(1 Pt 2):R109–R114

    CAS  PubMed  Google Scholar 

  26. Lopez MJ, Wong SK, Kishimoto I et al (1995) Salt-resistant hypertension in mice lacking the guanylyl cyclase-A receptor for atrial natriuretic peptide. Nature 378(6552):65–68

    Article  CAS  PubMed  Google Scholar 

  27. Tamura N, Ogawa Y, Chusho H et al (2000) Cardiac fibrosis in mice lacking brain natriuretic peptide. Proc Natl Acad Sci USA 97(8):4239–4244

    Article  CAS  PubMed  Google Scholar 

  28. Lanfear DE, Stolker J, Marsh S, Rich MW, McLeod HL (2006) Natriuretic Peptide Receptor 3 (NPR3) genotype modulates the relationship between B-Type Natriuretic Peptide (BNP) and left ventricular end-diastolic pressure. Therapy 3(6):765–771

    Article  CAS  Google Scholar 

  29. Lanfear DE, Marsh S, McLeod HL (2004) Sequence variants of natriuretic peptide receptor C are common and their frequency differs between African Americans and European Americans. J Card Fail 10(4 Suppl):S59

    Article  Google Scholar 

  30. Rahmutula D, Nakayama T, Soma M et al (2002) Structure and polymorphisms of the human natriuretic peptide receptor C gene. Endocrine 17(2):85–90

    Article  CAS  PubMed  Google Scholar 

  31. Rahmutula D, Nakayama T, Soma M et al (2001) Systematic screening of type B human natriuretic peptide receptor gene polymorphisms and association with essential hypertension. J Hum Hypertens 15(7):471–474

    Article  CAS  PubMed  Google Scholar 

  32. Sezaki N, Ishimaru F, Tabayashi T et al (2003) The type 1 CD10/neutral endopeptidase 24.11 promoter: functional characterization of the 5′-untranslated region. Br J Haematol 123(1):177–183

    Article  CAS  PubMed  Google Scholar 

  33. Wang TJ, Larson MG, Levy D et al (2003) Heritability and genetic linkage of plasma natriuretic peptide levels. Circulation 108(1):13–16

    Article  PubMed  Google Scholar 

  34. Knowles JW, Erickson LM, Guy VK, Sigel CS, Wilder JC, Maeda N (2003) Common variations in noncoding regions of the human natriuretic peptide receptor A gene have quantitative effects. Hum Genet 112(1):62–70

    Article  CAS  PubMed  Google Scholar 

  35. Nakayama T, Soma M, Saito S et al (2003) Missense mutation of exon 3 in the type A human natriuretic peptide receptor gene is associated with myocardial infarction. Med Sci Monit 9(12):CR505–CR510

    CAS  PubMed  Google Scholar 

  36. Pitzalis MV, Sarzani R, Dessi-Fulgheri P et al (2003) Allelic variants of natriuretic peptide receptor genes are associated with family history of hypertension and cardiovascular phenotype. J Hypertens 21(8):1491–1496

    Article  CAS  PubMed  Google Scholar 

  37. Nakayama T, Soma M, Takahashi Y, Rehemudula D, Kanmatsuse K, Furuya K (2000) Functional deletion mutation of the 5′-flanking region of type A human natriuretic peptide receptor gene and its association with essential hypertension and left ventricular hypertrophy in the Japanese. Circ Res 86(8):841–845

    CAS  PubMed  Google Scholar 

  38. Aoi N, Soma M, Nakayama T et al (2004) Variable number of tandem repeat of the 5′-flanking region of type-C human natriuretic peptide receptor gene influences blood pressure levels in obesity-associated hypertension. Hypertens Res 27(10):711–716

    Article  CAS  PubMed  Google Scholar 

  39. Tremblay J, Hum DH, Sanchez R et al (2003) TA repeat variation, Npr1 expression, and blood pressure: impact of the Ace locus. Hypertension 41(1):16–24

    Article  CAS  PubMed  Google Scholar 

  40. Rubattu S, Bigatti G, Evangelista A et al (2006) Association of atrial natriuretic peptide and type a natriuretic peptide receptor gene polymorphisms with left ventricular mass in human essential hypertension. J Am Coll Cardiol 48(3):499–505

    Article  CAS  PubMed  Google Scholar 

  41. Lanfear DE, Stolker JM, Marsh S, Rich MW, McLeod HL (2007) Genetic variation in the B-type natiuretic peptide pathway affects BNP levels. Cardiovasc Drugs Ther 21(1):55–62

    Article  CAS  PubMed  Google Scholar 

  42. Palmer BR, Frampton CM, Richards AM, Cameron VA, Nakayama T (2004) Absence of a NPR-A gene functional deletion allele in a postmyocardial infarction cohort from New Zealand. Circ Res 94(10):e86

    CAS  PubMed  Google Scholar 

  43. Nakayama T, Soma M, Mizutani Y et al (2002) A novel missense mutation of exon 3 in the type A human natriuretic peptide receptor gene: possible association with essential hypertension. Hypertens Res 25(3):395–401

    Article  CAS  PubMed  Google Scholar 

  44. Rehemudula D, Nakayama T, Soma M et al (1999) Structure of the type B human natriuretic peptide receptor gene and association of a novel microsatellite polymorphism with essential hypertension. Circ Res 84(5):605–610

    CAS  PubMed  Google Scholar 

  45. Vassalle C, Andreassi MG, Prontera C et al (2007) Influence of ScaI and natriuretic peptide (NP) clearance receptor polymorphisms of the NP System on NP concentration in chronic heart failure. Clin Chem 53(11):1886–1890

    Article  CAS  PubMed  Google Scholar 

  46. Sarzani R, Dessi-Fulgheri P, Salvi F et al (1999) A novel promoter variant of the natriuretic peptide clearance receptor gene is associated with lower atrial natriuretic peptide and higher blood pressure in obese hypertensives. J Hypertens 17(9):1301–1305

    Article  CAS  PubMed  Google Scholar 

  47. Helisalmi S, Hiltunen M, Vepsalainen S et al (2004) Polymorphisms in neprilysin gene affect the risk of Alzheimer’s disease in Finnish patients. J Neurol Neurosurg Psychiatry 75(12):1746–1748

    Article  CAS  PubMed  Google Scholar 

  48. Lilius L, Forsell C, Axelman K, Winblad B, Graff C, Tjernberg L (2003) No association between polymorphisms in the neprilysin promoter region and Swedish Alzheimer’s disease patients. Neurosci Lett 337(2):111–113

    Article  CAS  PubMed  Google Scholar 

  49. Nkeh B, Tiago A, Candy GP et al (2002) Association between an atrial natriuretic peptide gene polymorphism and normal blood pressure in subjects of African ancestry. Cardiovasc J S Afr 13(3):97–101

    PubMed  Google Scholar 

  50. Rubattu S, Stanzione R, Di Angelantonio E et al (2004) Atrial natriuretic peptide gene polymorphisms and risk of ischemic stroke in humans. Stroke 35(4):814–818

    Article  CAS  PubMed  Google Scholar 

  51. Meirhaeghe A, Sandhu MS, McCarthy MI et al (2007) Association between the T–381C polymorphism of the brain natriuretic peptide gene and risk of type 2 diabetes in human populations. Hum Mol Genet 16(11):1343–1350

    Article  CAS  PubMed  Google Scholar 

  52. Kosuge K, Soma M, Nakayama T et al (2007) A novel variable number of tandem repeat of the natriuretic peptide precursor B gene’s 5′-flanking region is associated with essential hypertension among Japanese females. Int J Med Sci 4(3):146–152

    CAS  PubMed  Google Scholar 

  53. Chiu C, Ingles J, Lind JM, Semsarian C (2006) Mutation analysis of the natriuretic peptide precursor B (NPPB) gene in patients with hypertrophic cardiomyopathy. DNA Seq 17(5):392–395

    Article  CAS  PubMed  Google Scholar 

  54. Tiret L, Mallet C, Poirier O et al (2000) Lack of association between polymorphisms of eight candidate genes and idiopathic dilated cardiomyopathy: the CARDIGENE study. J Am Coll Cardiol 35(1):29–35

    Article  CAS  PubMed  Google Scholar 

  55. Maisel AS, Clopton P, Krishnaswamy P et al (2004) Impact of age, race, and sex on the ability of B-type natriuretic peptide to aid in the emergency diagnosis of heart failure: results from the Breathing Not Properly (BNP) multinational study. Am Heart J 147(6):1078–1084

    Article  CAS  PubMed  Google Scholar 

  56. Mak GS, DeMaria A, Clopton P, Maisel AS (2004) Utility of B-natriuretic peptide in the evaluation of left ventricular diastolic function: comparison with tissue Doppler imaging recordings. Am Heart J 148(5):895–902

    Article  CAS  PubMed  Google Scholar 

  57. de Lemos JA, McGuire DK, Drazner MH (2003) B-type natriuretic peptide in cardiovascular disease. Lancet 362(9380):316–322

    Article  PubMed  Google Scholar 

  58. Stolker JM, Rich MW (2005) B-type natriuretic peptide provides independent and incremental value in predicting left ventricular end-diastolic pressure in elderly patients. Am J Geriatric Cardiol 14(2 Suppl):109

    Google Scholar 

  59. Stolker JM, Rich MW (2005) The combination of B-type natriuretic peptide and C-reactive protein provides incremental value in predicting outcomes among older patients referred for cardiac catheterization. Am J Geriatric Cardiol 14(2):109–110

    Google Scholar 

  60. Drazner MH, de Lemos JA (2005) Unexpected BNP levels in patients with advanced heart failure: a tale of caution and promise. Am Heart J 149(2):187–189

    Article  PubMed  Google Scholar 

  61. Troughton RW, Prior DL, Pereira JJ et al (2004) Plasma B-type natriuretic peptide levels in systolic heart failure: importance of left ventricular diastolic function and right ventricular systolic function. J Am Coll Cardiol 43(3):416–422

    Article  CAS  PubMed  Google Scholar 

  62. Maeda K, Tsutamoto T, Wada A, Hisanaga T, Kinoshita M (1998) Plasma brain natriuretic peptide as a biochemical marker of high left ventricular end-diastolic pressure in patients with symptomatic left ventricular dysfunction. Am Heart J 135(5 Pt 1):825–832

    Article  CAS  PubMed  Google Scholar 

  63. LaPointe MC (2005) Molecular regulation of the brain natriuretic peptide gene. Peptides 26(6):944–956

    Article  CAS  PubMed  Google Scholar 

  64. Waldo SW, Beede J, Isakson S et al (2008) Pro-B-type natriuretic peptide levels in acute decompensated heart failure. J Am Coll Cardiol 51(19):1874–1882

    Article  CAS  PubMed  Google Scholar 

  65. Colucci WS, Elkayam U, Horton DP et al (2000) Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure. Nesiritide Study Group. N Engl J Med 343(4):246–253

    Article  CAS  PubMed  Google Scholar 

  66. VMAC Study Group (2002) Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure: a randomized controlled trial. JAMA 287(12):1531–1540

    Google Scholar 

  67. Silver MA, Horton DP, Ghali JK, Elkayam U (2002) Effect of nesiritide versus dobutamine on short-term outcomes in the treatment of patients with acutely decompensated heart failure. J Am Coll Cardiol 39(5):798–803

    Article  CAS  PubMed  Google Scholar 

  68. Sackner-Bernstein JD, Skopicki HA, Aaronson KD (2005) Risk of worsening renal function with nesiritide in patients with acutely decompensated heart failure. Circulation 111(12):1487–1491

    Article  CAS  PubMed  Google Scholar 

  69. Sackner-Bernstein JD, Kowalski M, Fox M, Aaronson K (2005) Short-term risk of death after treatment with nesiritide for decompensated heart failure: a pooled analysis of randomized controlled trials. JAMA 293(15):1900–1905

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Henry Ford Heart and Vascular Institute, Section of Advanced Heart Failure and Cardiac Transplantation, Henry Ford Hospital, 2799 W. Grand Boulevard, K14, Detroit, MI, 48202, USA

    David E. Lanfear

Authors
  1. David E. Lanfear
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to David E. Lanfear.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lanfear, D.E. Genetic variation in the natriuretic peptide system and heart failure. Heart Fail Rev 15, 219–228 (2010). https://doi.org/10.1007/s10741-008-9113-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10741-008-9113-y

Keywords

Search

Navigation